Abt-301
Rectal Cancer
Mast Therapeutics, Inc.Phase 3Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 73/ 100
Competitive context
95 Active assets in the Rectal Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Capecitabine Gustave Roussy, Cancer Campus, Grand Paris | Phase 4 | BBB |
Eloxatin Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 | BBB |
FLUOROURACILUM Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 | BBB |
Calcium folinate pentahydrate Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 | BBB |
Irinotecan SCRI Development Innovations, LLC | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Abt-301 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →